Skip to main content

REGENERACION TISULAR, VASODILATACION ESPLACNICA Y BIOMARCADORES DE FIBROSIS EN LAS ENFERMEDADES HEPATICAS. EVALUACION EN PACIENTES Y MODELOS EXPERIMENTALES CON FIBROSIS.

BES-2013-063685

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Formación
Call Contratos Predoctorales
Call year 2013
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre FUNDACIÓ DE RECERCA CLÍNIC BARCELONA-INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease

  • Carvajal, Silvia
  • Perramón, Meritxell|||0000-0002-1944-8337
  • Oró, Denise
  • Casals, Eudald|||0000-0002-2900-7295
  • Fernández-Varo, Guillermo|||0000-0002-7776-3300
  • Parra-Robert, Marina
  • González de la Presa, Bernardino
  • Ribera, Jordi|||0000-0002-0288-4220
  • Pastor, Oscar|||0000-0002-4368-433X
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Puntes, Víctor|||0000-0001-8996-9499
  • Jiménez, Wladimiro|||0000-0002-9376-0214
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, ranging from steatosis to non-alcoholic steatohepatitis (NASH). Recently, cerium oxide nanoparticles (CeO₂NPs) have emerged as a new antioxidant agent with hepatoprotective properties in experimental liver disease. The aim of the current investigation was to elucidate whether CeO₂NPs display beneficial effects in an experimental model of NAFLD.Therefore, fifteen Wistar rats were subjected to a methionine and choline deficient diet (MCDD) for 6 weeks and intravenously treated with CeO₂NPs or vehicle during the weeks three and four of the diet. The effect of CeO₂NPs on serum biochemistry, hepatic steatosis, inflammation, fatty acid content and expression of reactive oxygen species (ROS) and lipid metabolism related genes was assessed. MCDD fed rats showed increased inflammation, enhanced hepatic lipid accumulation of both saturated and unsaturated fatty acids (FAs) and overexpression of genes related to fatty liver and ROS metabolism. Treatment with CeONPs was able to reduce the size and content of hepatocyte lipid droplets, the hepatic concentration of triglyceride- and cholesterol ester-derived FAs and the expression of several genes involved in cytokine, adipokine and chemokine signaling pathways. These findings suggest that CeO₂NPs could be of beneficial value in NAFLD.